<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427297</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00002049</org_study_id>
    <secondary_id>2R01HD023412-16</secondary_id>
    <secondary_id>06-1886-D 02</secondary_id>
    <nct_id>NCT00427297</nct_id>
  </id_info>
  <brief_title>Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya</brief_title>
  <official_title>Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (6-12 Month RCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Globally, children who acquire HIV-1 increasingly do so in the context of maternal
      antiretroviral prophylaxis. It is important to determine whether maternal antiretroviral
      prophylaxis should alter infant treatment regimens. Nevirapine (NVP) is commonly used for
      PMTCT and is also a commonly used first-line drug for treatment of pediatric HIV-1.
      Approximately half of infants exposed to NVP have detectable NVP resistance early in infancy,
      with loss of detectable resistance over time. Thus, if an HIV-1 infected child was exposed to
      single-dose NVP prophylaxis, the question remains whether NVP or any NNRTI can be used
      effectively in therapeutic regimens. Alternative PI-based regimens are associated with
      heat-lability, poor palatability, cumulative toxicity, and fewer salvage options. This poses
      challenges for pediatric PI-based highly active antiretroviral therapy (HAART) in settings
      without refrigeration and limited antiretroviral repertoire. It is plausible that in older
      NVP-exposed infants (older than 6 months since exposure) who are genotypically
      NVP-susceptible, that nevirapine will be effective and useful.

      We propose to study resistance in a pediatric HIV-1 clinical trial involving 100 children.
      Among children enrolled at between 6 and 18 months of age, we will provide real-time
      field-based genotypic NVP-resistance testing, and randomize 100 NVP-susceptible children to
      NVP-containing versus NVP-sparing HAART to compare therapeutic response, adverse events, and
      morbidity in the 2 arms during 2-year follow-up. Follow-up in these studies will be closely
      monitored by an external Data Safety and Monitoring Board (DSMB).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypotheses

        1. Infants older than 6 months who do not have detectable nevirapine resistance on
           genotypic testing will respond equivalently to a nevirapine-sparing or a
           nevirapine-containing HAART regimen, despite previous single-dose nevirapine exposure.

        2. Genotypic drug resistance levels may predict response to therapy and clinical
           progression.

      Specific Aims/Primary Objectives

        1. To compare response to therapy (viral levels, CD4%, growth, and morbidity) in infants
           without detectable nevirapine-resistance on population-based sequencing who are
           randomized to nevirapine-containing versus nevirapine-sparing HAART.

        2. To develop methods to detect and quantify nevirapine resistance mutations present at low
           frequency in the virus population in order to examine the relationship between the copy
           number of such variants and virologic failure of infants treated with
           nevirapine-containing HAART.

      Secondary Aim/Secondary Objective: To determine predictors of non-progression in these
      studies, including: age, time since nevirapine-exposure, adherence, HIV-1 specific immune
      responses, baseline HIV-1 RNA, CD4 percent, and immune activation.

      Design: Randomized clinical trial in which infant 6-18 months of age will be randomized to
      nevirapine containing versus nevirapine sparing HAART regimen and followed for 24 months.

      Population: HIV-1 infected infants (6-12 months) meeting eligibility will be enrolled.
      Infants who were exposed to nevirapine in-utero or following delivery, with no detectable
      resistance to nevirapine will be eligible for enrollment.

      Sample size: 100 infants will be enrolled (50 infants in each arm).

      Treatment: All infants will be treated with NVP containing or sparing HAART. The regimen will
      be prescribed according to WHO and Kenyan national guidelines on dosage and combination of
      antiretroviral drugs. The HAART regimen that will be used in this study are:

      First line regimen:

      For infants on NVP containing HAART

        -  AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)

        -  d4T/3TC/NVP (stavudine/lamivudine/nevirapine)

        -  ABC/3TC/NVP (abacavir/lamivudine/nevirapine)

      For infants on NVP sparing HAART

        -  AZT/3TC/ABC (zidovudine/lamivudine/abacavir)

        -  d4T/3TC/ABC (stavudine/lamivudine/abacavir)

      For children who have anaemia (Hb of &lt;8g/dl), AZT will be substituted for d4T.

      Second line regimen:

        -  ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir (kaletra))

        -  ABC / ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or
           efavirenz) Among children randomized to NVP sparing HAART, who will be initiated on a
           regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted
           with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be
           replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r
           containing regimen.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    There is no longer equipoise. DSMB recommended termination.
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Mortality</measure>
    <time_frame>2 years</time_frame>
    <description>Death during follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunologic Failure</measure>
    <time_frame>2 years</time_frame>
    <description>Immunologic treatment failure was defined as CD4% dropping below 15%, after a previous result greater than or equal to 15% (following along WHO Guidelines).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Failure</measure>
    <time_frame>2 years</time_frame>
    <description>Virologic treatment failure was defined as follow-up (at least 24 weeks after enrollment date) viral load &gt; 400 copies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Severe Adverse Events (Excluding Mortality)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>NVP-containing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants randomized to this arm will receive nevirapine-containing HAART regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVP-sparing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants randomized to this arm will receive nevirapine-sparing HAART</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)</intervention_name>
    <description>First line regimen</description>
    <arm_group_label>NVP-containing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>d4T/3TC/NVP (stavudine/lamivudine/nevirapine)</intervention_name>
    <description>First line regimen</description>
    <arm_group_label>NVP-containing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZT/3TC/ABC (zidovudine/lamivudine/abacavir)</intervention_name>
    <description>First line regimen</description>
    <arm_group_label>NVP-sparing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>d4T/3TC/ABC (stavudine/lamivudine/abacavir)</intervention_name>
    <description>First line regimen For children who have anaemia(Hb of&lt;8g/dl), AZT will be substituted for d4T.</description>
    <arm_group_label>NVP-sparing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)</intervention_name>
    <description>Second line regimen</description>
    <arm_group_label>NVP-sparing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)</intervention_name>
    <description>Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.</description>
    <arm_group_label>NVP-sparing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABC/3TC/NVP (abacavir/lamivudine/nevirapine)</intervention_name>
    <description>First line regimen</description>
    <arm_group_label>NVP-containing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6-18 months age

          -  HIV-1 DNA detection with confirmation (positive on two HIV-1 DNA filter paper tests)

          -  Mother exposed to NVP-containing PMTCT regimen during currently ended pregnancy and/or
             infant received NVP-containing PMTCT regimen

          -  Infant susceptible to NVP (i.e. no detectable NVP resistance on genotypic testing)

          -  Caregiver of infant plans to reside in Nairobi for at least 3 years

          -  Caregiver is able to provide sufficient location information

        Exclusion Criteria:

          -  Infant has received any prior antiretroviral therapy (expect prophylaxis for PMTCT)

          -  Infant has evidence of active tuberculosis

          -  Mother currently receiving NVP-containing HAART and breastfeeding the infant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace C John-Stewart, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dalton Wamalwa, MMed, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Paediatrics and Child Health, Kenyatta National Hospital, University of Nairobi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kenyatta National Hospital, University of Nairobi</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>January 22, 2007</study_first_submitted>
  <study_first_submitted_qc>January 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <results_first_submitted>June 29, 2018</results_first_submitted>
  <results_first_submitted_qc>July 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 27, 2018</results_first_posted>
  <last_update_submitted>July 27, 2018</last_update_submitted>
  <last_update_submitted_qc>July 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Grace John-Stewart</investigator_full_name>
    <investigator_title>Professor, Global Health, Medicine, Epidemiology, Pediatrics</investigator_title>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>Pediatric</keyword>
  <keyword>nevirapine</keyword>
  <keyword>HAART</keyword>
  <keyword>Resistance</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NVP-containing</title>
          <description>Infants randomized to this arm will receive nevirapine-containing HAART regimen
AZT/3TC/NVP (zidovudine/lamivudine/nevirapine): First line regimen
d4T/3TC/NVP (stavudine/lamivudine/nevirapine): First line regimen
ABC/3TC/NVP (abacavir/lamivudine/nevirapine): First line regimen</description>
        </group>
        <group group_id="P2">
          <title>NVP-sparing</title>
          <description>Infants randomized to this arm will receive nevirapine-sparing HAART
AZT/3TC/ABC (zidovudine/lamivudine/abacavir): First line regimen
d4T/3TC/ABC (stavudine/lamivudine/abacavir): First line regimen For children who have anaemia(Hb of&lt;8g/dl), AZT will be substituted for d4T.
ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir): Second line regimen
ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz): Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NVP-containing</title>
          <description>Infants randomized to this arm will receive nevirapine-containing HAART regimen
AZT/3TC/NVP (zidovudine/lamivudine/nevirapine): First line regimen
d4T/3TC/NVP (stavudine/lamivudine/nevirapine): First line regimen
ABC/3TC/NVP (abacavir/lamivudine/nevirapine): First line regimen</description>
        </group>
        <group group_id="B2">
          <title>NVP-sparing</title>
          <description>Infants randomized to this arm will receive nevirapine-sparing HAART
AZT/3TC/ABC (zidovudine/lamivudine/abacavir): First line regimen
d4T/3TC/ABC (stavudine/lamivudine/abacavir): First line regimen For children who have anaemia(Hb of&lt;8g/dl), AZT will be substituted for d4T.
ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir): Second line regimen
ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz): Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="6" upper_limit="10"/>
                    <measurement group_id="B2" value="8" lower_limit="6" upper_limit="10"/>
                    <measurement group_id="B3" value="7" lower_limit="6" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4%</title>
          <units>percentage of cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" lower_limit="14" upper_limit="29"/>
                    <measurement group_id="B2" value="18" lower_limit="13" upper_limit="25"/>
                    <measurement group_id="B3" value="21.5" lower_limit="13" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Mortality</title>
        <description>Death during follow-up</description>
        <time_frame>2 years</time_frame>
        <population>Analysis was conducted at DSMB termination of study with 15.6 person-years of follow-up time in the cohort overall; 8.5 person-years in NVP-containing and 7.1 person-years in NVP-sparing arm.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP-containing</title>
            <description>Infants randomized to this arm will receive nevirapine-containing HAART regimen
AZT/3TC/NVP (zidovudine/lamivudine/nevirapine): First line regimen
d4T/3TC/NVP (stavudine/lamivudine/nevirapine): First line regimen
ABC/3TC/NVP (abacavir/lamivudine/nevirapine): First line regimen</description>
          </group>
          <group group_id="O2">
            <title>NVP-sparing</title>
            <description>Infants randomized to this arm will receive nevirapine-sparing HAART
AZT/3TC/ABC (zidovudine/lamivudine/abacavir): First line regimen
d4T/3TC/ABC (stavudine/lamivudine/abacavir): First line regimen For children who have anaemia(Hb of&lt;8g/dl), AZT will be substituted for d4T.
ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir): Second line regimen
ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz): Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Mortality</title>
          <description>Death during follow-up</description>
          <population>Analysis was conducted at DSMB termination of study with 15.6 person-years of follow-up time in the cohort overall; 8.5 person-years in NVP-containing and 7.1 person-years in NVP-sparing arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunologic Failure</title>
        <description>Immunologic treatment failure was defined as CD4% dropping below 15%, after a previous result greater than or equal to 15% (following along WHO Guidelines).</description>
        <time_frame>2 years</time_frame>
        <population>15.6 person years of follow-up overall at time of DSMB closure of study</population>
        <group_list>
          <group group_id="O1">
            <title>NVP-containing</title>
            <description>Infants randomized to this arm will receive nevirapine-containing HAART regimen
AZT/3TC/NVP (zidovudine/lamivudine/nevirapine): First line regimen
d4T/3TC/NVP (stavudine/lamivudine/nevirapine): First line regimen
ABC/3TC/NVP (abacavir/lamivudine/nevirapine): First line regimen</description>
          </group>
          <group group_id="O2">
            <title>NVP-sparing</title>
            <description>Infants randomized to this arm will receive nevirapine-sparing HAART
AZT/3TC/ABC (zidovudine/lamivudine/abacavir): First line regimen
d4T/3TC/ABC (stavudine/lamivudine/abacavir): First line regimen For children who have anaemia(Hb of&lt;8g/dl), AZT will be substituted for d4T.
ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir): Second line regimen
ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz): Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunologic Failure</title>
          <description>Immunologic treatment failure was defined as CD4% dropping below 15%, after a previous result greater than or equal to 15% (following along WHO Guidelines).</description>
          <population>15.6 person years of follow-up overall at time of DSMB closure of study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Failure</title>
        <description>Virologic treatment failure was defined as follow-up (at least 24 weeks after enrollment date) viral load &gt; 400 copies.</description>
        <time_frame>2 years</time_frame>
        <population>15.6 person years of follow-up overall at time of DSMB closure of study</population>
        <group_list>
          <group group_id="O1">
            <title>NVP-containing</title>
            <description>Infants randomized to this arm will receive nevirapine-containing HAART regimen
AZT/3TC/NVP (zidovudine/lamivudine/nevirapine): First line regimen
d4T/3TC/NVP (stavudine/lamivudine/nevirapine): First line regimen
ABC/3TC/NVP (abacavir/lamivudine/nevirapine): First line regimen</description>
          </group>
          <group group_id="O2">
            <title>NVP-sparing</title>
            <description>Infants randomized to this arm will receive nevirapine-sparing HAART
AZT/3TC/ABC (zidovudine/lamivudine/abacavir): First line regimen
d4T/3TC/ABC (stavudine/lamivudine/abacavir): First line regimen For children who have anaemia(Hb of&lt;8g/dl), AZT will be substituted for d4T.
ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir): Second line regimen
ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz): Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Failure</title>
          <description>Virologic treatment failure was defined as follow-up (at least 24 weeks after enrollment date) viral load &gt; 400 copies.</description>
          <population>15.6 person years of follow-up overall at time of DSMB closure of study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Severe Adverse Events (Excluding Mortality)</title>
        <time_frame>2 years</time_frame>
        <population>15.6 person-years of follow-up overall at time of DSMB closure of study</population>
        <group_list>
          <group group_id="O1">
            <title>NVP-containing</title>
            <description>Infants randomized to this arm will receive nevirapine-containing HAART regimen
AZT/3TC/NVP (zidovudine/lamivudine/nevirapine): First line regimen
d4T/3TC/NVP (stavudine/lamivudine/nevirapine): First line regimen
ABC/3TC/NVP (abacavir/lamivudine/nevirapine): First line regimen</description>
          </group>
          <group group_id="O2">
            <title>NVP-sparing</title>
            <description>Infants randomized to this arm will receive nevirapine-sparing HAART
AZT/3TC/ABC (zidovudine/lamivudine/abacavir): First line regimen
d4T/3TC/ABC (stavudine/lamivudine/abacavir): First line regimen For children who have anaemia(Hb of&lt;8g/dl), AZT will be substituted for d4T.
ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir): Second line regimen
ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz): Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Severe Adverse Events (Excluding Mortality)</title>
          <population>15.6 person-years of follow-up overall at time of DSMB closure of study</population>
          <units>event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>15.6 person years overall of follow-up at time of DSMB closure of study</desc>
      <group_list>
        <group group_id="E1">
          <title>NVP-containing</title>
          <description>NVP-containing (AZT/3TC/NVP; d4T/3TC/NVP; or ABC/3TC/NVP) antiretroviral triple combination therapy.
Second-line regimens based on the WHO pediatric treatment guidelines, 2006.</description>
        </group>
        <group group_id="E2">
          <title>NVP-sparing</title>
          <description>NVP-sparing (AZT/3TC/LPV/r; or d4T/3TC/LPV/r1) antiretroviral triple combination therapy.
Second-line regimens based on the WHO pediatric treatment guidelines, 2006.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Severe anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperamylasemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia or respiratory</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Milestone regression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study team suggested discontinuation of the trial and the DSMB concurred based on slow accrual and based on new data that emerged after the RCT was initiated which made the trial question less relevant.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Grace John-Stewart</name_or_title>
      <organization>University of Washington</organization>
      <phone>206 5434278</phone>
      <email>gjohn@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

